EP3843747A4 - TAUROLIDINE TREATMENT FOR MYC-EXPRESSING TUMORS IN MAMMALIAN BODIES - Google Patents

TAUROLIDINE TREATMENT FOR MYC-EXPRESSING TUMORS IN MAMMALIAN BODIES Download PDF

Info

Publication number: EP3843747A4
Authority: EP; European Patent Office
Prior art keywords: myc; expressing tumors; mammalian bodies; taurolidine treatment; taurolidine
Prior art date: 2018-08-31
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Pending

Application number

EP19854097.3A

Other languages

German (de)

French (fr)

Other versions

EP3843747A1 (en

Inventor

Bruce Reidenberg

Robert Diluccio

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Cormedix Inc

Original Assignee

Cormedix Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2018-08-31

Filing date

2019-09-03

Publication date

2022-12-28

2019-09-03 Application filed by Cormedix Inc filed Critical Cormedix Inc

2021-07-07 Publication of EP3843747A1 publication Critical patent/EP3843747A1/en

2022-12-28 Publication of EP3843747A4 publication Critical patent/EP3843747A4/en

Status Pending legal-status Critical Current

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/549—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/5123—Organic compounds, e.g. fats, sugars
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nanotechnology (AREA)
Optics & Photonics (AREA)
Physics & Mathematics (AREA)
Biomedical Technology (AREA)
Oil, Petroleum & Natural Gas (AREA)
Dermatology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicinal Preparation (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

EP19854097.3A 2018-08-31 2019-09-03 TAUROLIDINE TREATMENT FOR MYC-EXPRESSING TUMORS IN MAMMALIAN BODIES Pending EP3843747A4 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US201862725650P	2018-08-31	2018-08-31
PCT/US2019/049266 WO2020047530A1 (en)	2018-08-31	2019-09-03	Taurolidine treatment for myc-expressing tumors in mammalian bodies

Publications (2)

Publication Number	Publication Date
EP3843747A1 EP3843747A1 (en)	2021-07-07
EP3843747A4 true EP3843747A4 (en)	2022-12-28

Family

ID=69643283

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
EP19854097.3A Pending EP3843747A4 (en)	2018-08-31	2019-09-03	TAUROLIDINE TREATMENT FOR MYC-EXPRESSING TUMORS IN MAMMALIAN BODIES

Country Status (7)

Country	Link
EP (1)	EP3843747A4 (en)
JP (2)	JP2021535167A (en)
KR (1)	KR20210054544A (en)
CN (1)	CN113226325A (en)
AU (1)	AU2019331913B2 (en)
CA (1)	CA3111100A1 (en)
WO (1)	WO2020047530A1 (en)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2001039762A2 (en) *	1999-12-06	2001-06-07	Rhode Island Hospital, A Lifespan Partner	Use of taurolidine or taurultam for the manufacture of a medicament for the treatment of tumors of the central nervous system
US20040176360A1 (en) *	1999-12-06	2004-09-09	Paul Calabresi	Use of taurolidine to treat tumors
WO2007077528A1 (en) *	2006-01-06	2007-07-12	Ed. Geistlich Soehne Ag Fuer Chemische Industrie	Irradiated compositions and treatment of cancers with radiation in combination with taurolidine and/or taurultam
US20080171738A1 (en) *	2001-04-03	2008-07-17	Ed. Geistlich Soehne Ag Fuer Chemische Industrie	Treatment of Breast Cancer
WO2017158570A1 (en) *	2016-03-18	2017-09-21	Geistlich Pharma Ag	Method of treating triple negative breast cancer

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB9005856D0 (en) *	1990-03-15	1990-05-09	Geistlich Soehne Ag	Compositions
US7151099B2 (en) *	1998-07-31	2006-12-19	Ed. Geistlich Soehne Ag Fuer Chemische Industrie	Use of taurolidine and/or taurultam for treatment of abdominal cancer and/or for the prevention of metastases
US20050124608A1 (en) *	2001-04-03	2005-06-09	Redmond H. P.	Treatment of cancers
US20030027818A1 (en) *	2001-04-03	2003-02-06	Redmond H. Paul	Treatment of cancers
GB9716219D0 (en) *	1997-07-31	1997-10-08	Geistlich Soehne Ag	Prevention of metastases
US20030092707A1 (en) *	2001-10-19	2003-05-15	Redmond H. Paul	Treatment of breast cancer
CA2482687C (en) *	2003-09-29	2012-11-20	Ed. Geistlich Soehne Ag Fuer Chemische Industrie	Treatment of mesothelioma
US7964571B2 (en) *	2004-12-09	2011-06-21	Egen, Inc.	Combination of immuno gene therapy and chemotherapy for treatment of cancer and hyperproliferative diseases
WO2007020509A1 (en) *	2005-08-15	2007-02-22	Ed. Geistlich Soehne Ag Fuer Chemische Industrie	Combination of methylol transfer agents with tumour-inhibiting proteins or peptides and the use thereof for the treatment of cancer or tumor growth
WO2011151722A2 (en) *	2010-06-01	2011-12-08	Geistlich Pharma Ag	Methods and compositions for oral pharmaceutical therapy
JP7614714B2 (en) *	2016-01-11	2025-01-16	コーメディクス・インコーポレーテッド	Therapeutic nanoparticles for the treatment of neuroblastoma and other cancers
WO2020047113A1 (en) *	2018-08-28	2020-03-05	Cormedix Inc.	Neuroblastoma treatment with taurolidine hydrolysis products

2019
- 2019-09-03 EP EP19854097.3A patent/EP3843747A4/en active Pending
- 2019-09-03 CN CN201980072806.2A patent/CN113226325A/en active Pending
- 2019-09-03 JP JP2021511591A patent/JP2021535167A/en active Pending
- 2019-09-03 KR KR1020217009412A patent/KR20210054544A/en active Pending
- 2019-09-03 CA CA3111100A patent/CA3111100A1/en active Pending
- 2019-09-03 WO PCT/US2019/049266 patent/WO2020047530A1/en not_active Ceased
- 2019-09-03 AU AU2019331913A patent/AU2019331913B2/en active Active
2025
- 2025-05-28 JP JP2025088837A patent/JP2025128194A/en active Pending

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2001039762A2 (en) *	1999-12-06	2001-06-07	Rhode Island Hospital, A Lifespan Partner	Use of taurolidine or taurultam for the manufacture of a medicament for the treatment of tumors of the central nervous system
US20040176360A1 (en) *	1999-12-06	2004-09-09	Paul Calabresi	Use of taurolidine to treat tumors
US20080171738A1 (en) *	2001-04-03	2008-07-17	Ed. Geistlich Soehne Ag Fuer Chemische Industrie	Treatment of Breast Cancer
WO2007077528A1 (en) *	2006-01-06	2007-07-12	Ed. Geistlich Soehne Ag Fuer Chemische Industrie	Irradiated compositions and treatment of cancers with radiation in combination with taurolidine and/or taurultam
WO2017158570A1 (en) *	2016-03-18	2017-09-21	Geistlich Pharma Ag	Method of treating triple negative breast cancer

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
ANGERER JÜRGEN ET AL: "Opinion on methylene glycol", 26 June 2012 (2012-06-26), pages 1 - 14, XP055982131, Retrieved from the Internet <URL:chrome-extension://efaidnbmnnnibpcajpcglclefindmkaj/https://ec.europa.eu/health/scientific_committees/consumer_safety/docs/sccs_o_097.pdf> [retrieved on 20221116] *
ANONYMOUS: "Cormedix Inc. announces agreement with nanoproteagen for its proprietary nanoparticle technology, Nanopro TM, in combination with CRMD-005 for pediatric neuroblastoma", INTERNET CITATION, 11 May 2016 (2016-05-11), XP002792142, Retrieved from the Internet <URL:http://www.cormedix.com/cormedix-inc-announces-agreement-with-nanoproteagen-for-its-proprietary-nanoparticle-technology-nanopro-in-combination-with-crmd-005-for-pediatric-neuroblastoma-2/> [retrieved on 20190617] *
JONES D S ET AL: "A study of the stability of taurolidine in plasma and protein-free serum", INTERNATIONAL JOURNAL OF PHARMACEUTICS, ELSEVIER, NL, vol. 64, no. 2-3, 30 October 1990 (1990-10-30), pages R1 - R4, XP023736496, ISSN: 0378-5173, [retrieved on 19901030], DOI: 10.1016/0378-5173(90)90278-C *
KEVIN MARLEY ET AL: "Pharmacokinetic study and evaluation of the safety of taurolidine for dogs with osteosarcoma", JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, BIOMED CENTRAL LTD, LONDON UK, vol. 32, no. 1, 11 October 2013 (2013-10-11), pages 74, XP021165358, ISSN: 1756-9966, DOI: 10.1186/1756-9966-32-74 *
LUO JUHUA ET AL: "Association between Six Environmental Chemicals and Lung Cancer Incidence in the United States", JOURNAL OF ENVIRONMENTAL AND PUBLIC HEALTH, vol. 2011, no. 9, 1 January 2011 (2011-01-01), pages 1 - 9, XP055982102, ISSN: 1687-9805, Retrieved from the Internet <URL:https://downloads.hindawi.com/journals/jeph/2011/463701.pdf> DOI: 10.1155/2011/463701 *
MÖHLER HANS ET AL: "Redox-directed cancer therapeutics: Taurolidine and Piperlongumine as broadly effective antineoplastic agents (Review)", INTERNATIONAL JOURNAL OF ONCOLOGY, vol. 45, no. 4, 1 October 2014 (2014-10-01), GR, pages 1329 - 1336, XP055945228, ISSN: 1019-6439, Retrieved from the Internet <URL:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4151817/pdf/ijo-45-04-1329.pdf> DOI: 10.3892/ijo.2014.2566 *
See also references of WO2020047530A1 *
STENDEL RUEDIGER ET AL: "Pharmacokinetics of Taurolidine following Repeated Intravenous Infusions Measured by HPLC-ESI-MS/MS of the Derivatives Taurultame and Taurinamide in Glioblastoma Patients :", CLINICAL PHARMACOKINETICS., vol. 46, no. 6, 1 January 2007 (2007-01-01), NZ, pages 513 - 524, XP055945305, ISSN: 0312-5963, Retrieved from the Internet <URL:http://dx.doi.org/10.2165/00003088-200746060-00005> DOI: 10.2165/00003088-200746060-00005 *

Also Published As

Publication number	Publication date
JP2021535167A (en)	2021-12-16
AU2019331913A1 (en)	2021-04-29
CA3111100A1 (en)	2020-03-05
AU2019331913B2 (en)	2025-06-26
EP3843747A1 (en)	2021-07-07
JP2025128194A (en)	2025-09-02
WO2020047530A1 (en)	2020-03-05
CN113226325A (en)	2021-08-06
KR20210054544A (en)	2021-05-13

Publication	Publication Date	Title
MA51677A (en)	2020-12-02	CANCER TREATMENT METHODS USING ANTI-PD-1 ANTIBODIES
MA47208A (en)	2019-11-13	CANCER TREATMENT METHODS USING ANTI-PD-1 ANTIBODIES
EP3431105A4 (en)	2019-04-03	MEDICINAL COMPOSITION FOR THE TREATMENT OF CANCER
MA49760A (en)	2020-06-10	MAVACAMTEN FOR USE IN THE TREATMENT OF HYPERTROPHIC CARDIOMYOPATHY
EP3440493A4 (en)	2019-05-22	SAMPLE TREATMENT FOR MICROSCOPY
EP3766497A4 (en)	2021-12-08	MEDICINE FOR THE TREATMENT OF COUGH
EP3641811A4 (en)	2021-03-31	BIOACTIVE IMMUNO-PRIVILEGE KIDNEY CELLS FOR THE TREATMENT OF KIDNEY DISEASE
MA55218A (en)	2022-01-12	ESKETAMINE FOR THE TREATMENT OF DEPRESSION
EP3880849A4 (en)	2022-08-24	PERIPHERAL BLOOD MICRORNA MARKER FOR DIAGNOSIS IN NON-SMALL CELL LUNG CANCER
MA52218A (en)	2021-02-17	TREATMENT OF CANCERS ASSOCIATED WITH TRK
EP3740246C0 (en)	2023-06-07	DISRUPTION OF THE LINC COMPLEX FOR THE TREATMENT OF LAMINOPATHIES
EP3843737A4 (en)	2022-06-01	PDE9 INHIBITORS FOR THE TREATMENT OF SICKLE CELL DISEASE
EP3285795A4 (en)	2019-02-20	ENTERPRISE ADMINISTERED OLIGOPEPTIDES FOR THE TREATMENT OF TYPE 2 DIABETES
EP3773221A4 (en)	2021-09-15	TREATMENT FOR HYDROCEPHALIA
MA56184A (en)	2022-04-20	AFABICIN FOR USE IN THE TREATMENT OF BACTERIAL INFECTIONS INVOLVING BIOFILM
MA53614A (en)	2021-07-21	PROTEIN FOR THE TREATMENT OF INFLAMMATORY DISEASES
MA46086A (en)	2019-07-10	DOSAGE SCHEDULE FOR THE TREATMENT OF SOLID TUMORS
EP3426307A4 (en)	2019-10-23	USE OF DREADD FOR NEURONAL MODULATION IN THE TREATMENT OF NEURONAL DISEASES
EP4373525A4 (en)	2025-05-07	TREATMENT COMBINATIONS FOR CANCER
EP3813870C0 (en)	2023-11-15	CCR5 INHIBITOR FOR USE IN THE TREATMENT OF CANCER
MA55982A (en)	2022-03-23	PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF TUMORS
EP3411062A4 (en)	2019-09-25	USE OF CD24 PROTEINS FOR THE TREATMENT OF DISEASES WITH LEPTIN DEFICIENCY
MA52499A (en)	2021-04-14	CANCER TREATMENT ASSOCIATIONS
EP3406258A4 (en)	2019-03-13	MEDICAMENT FOR USE IN THE TREATMENT OF GOUTTE
EP3903725A4 (en)	2022-08-31	JUNCTION STRUCTURE FOR TREATMENT

Legal Events

Date	Code	Title	Description
2020-03-07	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE
2021-06-04	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE
2021-06-12	PUAI	Public reference made under article 153(3) epc to a published international application that has entered the european phase	Free format text: ORIGINAL CODE: 0009012
2021-07-07	17P	Request for examination filed	Effective date: 20210326
2021-07-07	AK	Designated contracting states	Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
2021-12-08	DAV	Request for validation of the european patent (deleted)
2021-12-08	DAX	Request for extension of the european patent (deleted)
2022-08-31	RIC1	Information provided on ipc code assigned before grant	Ipc: A61K 9/50 20060101ALI20220727BHEP Ipc: A61K 38/19 20060101ALI20220727BHEP Ipc: A61K 31/549 20060101AFI20220727BHEP
2022-12-28	A4	Supplementary search report drawn up and despatched	Effective date: 20221128
2022-12-28	RIC1	Information provided on ipc code assigned before grant	Ipc: A61K 9/50 20060101ALI20221122BHEP Ipc: A61K 38/19 20060101ALI20221122BHEP Ipc: A61K 31/549 20060101AFI20221122BHEP
2024-11-29	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: EXAMINATION IS IN PROGRESS
2025-01-01	17Q	First examination report despatched	Effective date: 20241128